Efgartigimod - Open Access .click

Results 171 to 180 of about 1,470 (198)

Some of the next articles are maybe not open access.

Efgartigimod Alfa Injection (Vyvgart SC)

Canadian Journal of Health Technologies
Canada’s Drug Agency (CDA-AMC) recommends that Vyvgart SC be reimbursed by public drug plans as monotherapy for adult patients with active chronic inflammatory demyelinating polyneuropathy (CIDP), if certain conditions are met. Vyvgart SC should only be covered for adults with CIDP confirmed by electrodiagnostic testing, or for adults with possible ...
openaire +1 more source

Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial

Lancet, The, 2023
Catherine M Broome +2 more
exaly

Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)

Neurotherapeutics
James F Howard, Tuan Vu, Jan L De Bleecker +2 more
exaly

Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events

Muscle and Nerve
Madeline L Singer, Paul McIntosh, Colin Quinn +2 more
exaly

Case report: Efgartigimod is a novel therapeutic option for ocular myasthenia gravis: a report of 2 cases

Frontiers in Immunology
Ruixia Zhu
exaly

Study of efgartigimod as a new treatment for pemphigus

British Journal of Dermatology, 2022
openaire +1 more source

Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases

Expert Review of Clinical Immunology
Kelly G Gwathmey +2 more
exaly